ClinicalTrials.gg
CompletedNCT02247349Updated Mar 5, 2024Results posted

BMS-986012 in Relapsed/Refractory SCLC

A Phase 1/2 interventional study of BMS-986012 (anti-fucosyl-GM1) and Nivolumab in Small Cell Lung Cancer, sponsored by Bristol-Myers Squibb. Completed at 16 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-05.

Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
106
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb — 2 open to participants now, 2 under way, 1 of them phase 3. Small Cell Lung Carcinoma · Bristol-Myers Squibb.

Enrollment
7th of 17
106 · median 92
Started
2014
with 1 other
Phase 1/2
2 of 19
1 open now
Registered
9th of 19
by date

Among the 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb, this one is the 7th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2014, is one of 2 in phase 1/2, and was the 9th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

2 of the 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety, tolerability, pharmacokinetics, immunogenicity, antitumor activity and pharmacodynamics of BMS-986012 alone and in combination with nivolumab in patients with relapsed/refractory SCLC.

03

Conditions studied

  • Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Histological or cytological confirmed small cell lung cancer (SCLC)
  • Performance Status 0-1
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Known or suspected
  • Small cell cancer not lung in origin
  • Significant or acute medical illness
  • Uncontrolled or significant cardiac disease
  • Infection
  • ≥ Grade 2 peripheral neuropathy
  • Concomitant
  • related disease or known or suspected HIV+
  • or C infection
  • abnormalities as defined by the protocol
  • Allergies or to monoclonal antibodies, BMS-986012 or related compounds, including fucosyl-GM1 vaccine and Nivolumab

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    Dose Escalation (Monotherapy) Dose -1

    BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity

    Biological: BMS-986012 (anti-fucosyl-GM1)

  • Experimental
    Dose Escalation (Monotherapy) Dose 1

    BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity

    Biological: BMS-986012 (anti-fucosyl-GM1)

  • Experimental
    Dose Escalation (Monotherapy) Dose 2

    BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity

    Biological: BMS-986012 (anti-fucosyl-GM1)

  • Experimental
    Dose Escalation (Monotherapy) Dose 3

    BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity

    Biological: BMS-986012 (anti-fucosyl-GM1)

  • Experimental
    Dose Escalation (Monotherapy) Dose 4

    BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity

    Biological: BMS-986012 (anti-fucosyl-GM1)

  • Experimental
    Dose Expansion (Monotherapy)- Cohort A (Refractory)

    BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity

    Biological: BMS-986012 (anti-fucosyl-GM1)

  • Experimental
    Dose Expansion (Monotherapy) Cohort B (Refractory)

    BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity

    Biological: BMS-986012 (anti-fucosyl-GM1)

  • Experimental
    Dose Expansion (Monotherapy) Cohort C (Sensitive)

    BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity

    Biological: BMS-986012 (anti-fucosyl-GM1)

  • Experimental
    Dose Expansion (Monotherapy) Cohort D (Sensitive)

    BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity

    Biological: BMS-986012 (anti-fucosyl-GM1)

  • Experimental
    Dose Escalation (Combination) Dose 1

    BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity in combination with Nivolumab specified dose on specified days

    Biological: BMS-986012 (anti-fucosyl-GM1) · Biological: Nivolumab

  • Experimental
    Dose Escalation (Combination) Dose 2

    BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity in combination with Nivolumab specified dose on specified days

    Biological: BMS-986012 (anti-fucosyl-GM1) · Biological: Nivolumab

  • Experimental
    Dose Expansion (Combination)- (Refractory and Sensitive)

    BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity in combination with Nivolumab specified dose on specified days

    Biological: BMS-986012 (anti-fucosyl-GM1) · Biological: Nivolumab

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs)

    Number of participants with any grade adverse events (AEs). An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

    Time frame: From first dose to 100 days post last dose (Up to 64 months)

  2. Number of Participants With Serious Adverse Events (SAEs)

    Number of participants with any grade serious adverse events (SAEs). A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: * results in death * is life-threatening * requires inpatient hospitalization or causes prolongation of existing hospitalization * results in persistent or significant disability/incapacity * is a congenital anomaly/birth defect * is an important medical event Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

    Time frame: From first dose to 100 days post last dose (Up to 64 months)

  3. Number of Participants With Adverse Events (AEs) Leading to Discontinuation

    Number of participants with any grade adverse events (AEs) leading to discontinuation. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

    Time frame: From first dose to 100 days post last dose (Up to 64 months)

  4. Number of Participants Who Died

    Number of participants who died due to any cause.

    Time frame: From first dose to 100 days post last dose (Up to 64 months)

  5. Number of Participants With Abnormal Hepatic Test

    Number of participants with laboratory abnormalities in specific hepatic tests. The number of participants with the following laboratory abnormalities from on-treatment evaluations will be summarized: * ALT or AST \> 5xULN, \> 3xULN, and \> 2xULN * Any of ALT, AST, Total Bilirubin or ALP \> 8xULN * Total bilirubin \> 3xULN ALT = Alanine Aminotransferase; AST = Aspartate Aminotransferase; ULN = Upper Limit of Normal

    Time frame: From first dose to 100 days post last dose (Up to 64 months)

Secondary outcomes

  1. BMS-986012 Maximum Observed Serum Concentration (Cmax)

    BMS-986012 maximum observed serum concentration (Cmax).

    Time frame: Cycle 1 day 1, cycle 3 day 1 (including pre-dose, 1, 2, 4, 8, 24, 72, 168, 336 hours post dose)

  2. BMS-986012 Time of Maximum Observed Serum Concentration (Tmax)

    BMS-986012 time of maximum observed serum concentration (Tmax).

    Time frame: Cycle 1 day 1, cycle 3 day 1 (including pre-dose, 1, 2, 4, and 8 hours post dose)

  3. BMS-986012 Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC (0-T))

    BMS-986012 area under the serum concentration-time curve from time zero to time of last quantifiable concentration (AUC (0-T)).

    Time frame: Cycle 1 day 1, cycle 3 day 1 (including pre-dose, 1, 2, 4, 8, 24, 72, 168, 336 hours post dose)

  4. BMS-986012 Area Under the Serum Concentration-time Curve in One Dosing Interval AUC (TAU)

    BMS-986012 area under the serum concentration-time curve in one dosing interval AUC (TAU).

    Time frame: Cycle 1 day 1, cycle 3 day 1 (including pre-dose, 1, 2, 4, 8, 24, 72, 168, 336 hours post dose)

  5. BMS-986012 Observed Serum Concentration at the End of a Dosing Interval (Ctau)

    BMS-986012 observed serum concentration at the end of a dosing interval (Ctau).

    Time frame: Cycle 1 day 1, cycle 3 day 1 (including pre-dose, 1, 2, 4, 8, 24, 72, 168, 336 hours post dose)

  6. BMS-986012 Total Body Clearance (CLT)

    BMS-986012 total body clearance (CLT).

    Time frame: Cycle 1 day 1, cycle 3 day 1 (including pre-dose, 1, 2, 4, 8, 24, 72, 168, 336 hours post dose)

  7. BMS-986012 Trough Observed Serum Concentration (Ctrough)

    BMS-986012 trough observed serum concentration (Ctrough).

    Time frame: Cycle 2 day 1, cycle 3 day 1, cycle 4 day 1, cycle 7 day 1, cycle 11 day 1. cycle 15 day 1 (including pre-dose, 1, 2, 4, 8, 24, 72, 168, 336 hours post dose)

  8. BMS-986012 Average Concentration Over a Dosing Interval (Css-avg)

    BMS-986012 Average concentration over a dosing interval (\[AUC(TAU)/tau\] (Css-avg).

    Time frame: Cycle 3 day 1 (including pre-dose, 1, 2, 4, and 8 hours post dose)

  9. BMS-986012 Accumulation Index (AI_AUC)

    BMS-986012 accumulation index. Ratio of an exposure measure at steady state to that after the first dose.

    Time frame: Cycle 3 day 1 (including pre-dose, 1, 2, 4, and 8 hours post dose)

  10. BMS-986012 Cmax Accumulation Index (AI_Cmax)

    BMS-986012 Cmax accumulation index (AI_Cmax). Ratio of an exposure measure at steady state to that after the first dose.

    Time frame: Cycle 3 day 1 (including pre-dose, 1, 2, 4, and 8 hours post dose)

  11. BMS-986012 Ctau Accumulation Index (AI_Ctau)

    BMS-986012 Ctau accumulation index (AI_Ctau). Ratio of an exposure measure at steady state to that after the first dose.

    Time frame: Cycle 3 day 1 (including pre-dose, 1, 2, 4, and 8 hours post dose)

  12. BMS-986012 Effective Elimination (T-HALFeff)

    BMS-986012 effective elimination (T-HALFeff) that explains the degree of accumulation observed for a specific exposure measure.

    Time frame: Cycle 3 day 1 (including pre-dose, 1, 2, 4, and 8 hours post dose)

  13. Best Overall Response (BOR)

    BOR defined as the best response designation over the study as a whole. Complete Response (CR) = Disappearance of all target lesions; Partial Response (PR) = At least a 30% decrease in the sum of diameters of target lesions; Stable Disease (SD) = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; Progressive Disease (PD) = At least a 20% increase in the sum of diameters of target lesions and the sum must demonstrate an absolute increase of at least 5 mm

    Time frame: From first dose to the last tumor assessment prior to subsequent therapy (Up to 97 months)

  14. Objective Response Rate (ORR)

    ORR is defined as the percent of participants whose BOR is either CR or PR. Complete Response (CR) = Disappearance of all target lesions; Partial Response (PR) = At least a 30% decrease in the sum of diameters of target lesions; Progressive Disease (PD) = At least a 20% increase in the sum of diameters of target lesions and the sum must demonstrate an absolute increase of at least 5 mm

    Time frame: From first dose date to the date of first documented disease progression (Up to 97 months)

  15. Duration of Response (DoR)

    DoR is defined as the time from first response (CR or PR) to the date of the first documented tumor progression as determined using RECIST 1.1 criteria or death due to any cause, whichever occurs first. Participants who remain alive and have not progressed will be censored on the date of their last tumor assessment. Complete Response (CR) = Disappearance of all target lesions; Partial Response (PR )= At least a 30% decrease in the sum of diameters of target lesions; Progressive Disease (PD) = At least a 20% increase in the sum of diameters of target lesions and the sum must demonstrate an absolute increase of at least 5 mm Median DOR will only be evaluated provided there are enough responding participants to warrant inclusion.

    Time frame: From the date of first dose to the date of the first documented tumor progression or death due to any cause, whichever occurs first (Up to 97 months)

  16. Progression Free Survival (PFS)

    PFS is defined as the time from the date of first dose of study medication to the date of the first objective documentation of tumor progression or death due to any cause, if death occurred within 100 days after last BMS-986012 dose. Progressive Disease (PD) = At least a 20% increase in the sum of diameters of target lesions and the sum must demonstrate an absolute increase of at least 5 mm

    Time frame: From first dose to the date of first documented disease progression or death due to any cause, if death occurred within 100 days after last BMS-986012 dose (Up to 97 months)

  17. Progression Free Survival Rate (PFSR)

    PFSR is defined as the percent of participants who remain progression free and surviving at "t" weeks (t= 12, 24, 36, 48, 60, 72). Progressive Disease (PD)=At least a 20% increase in the sum of diameters of target lesions and the sum must demonstrate an absolute increase of at least 5 mm

    Time frame: Weeks 12, 24, 36, 48, 60, 72

  18. Number of Participants With Anti-BMS-986012 Antibodies (ADA)

    Number of participants with anti-BMS-986012 antibodies (ADA) with status as baseline ADA positive, ADA positive and ADA negative. Baseline ADA positive participant is a participant with baseline ADA positive sample (Day 1 predose). ADA-positive participant is a participant with at least one ADA positive sample relative to baseline at any time after initiation of treatment during the defined observation time period. ADA negative participant is a participant with no ADA positive sample after the initiation of treatment.

    Time frame: From first dose to 100 days following the last BMS-986012 dose (Up to 64 months)

07

Results

Posted Mar 5, 2024

Participant flow

Participant flow — Overall Study
MilestoneBMS 70mgBMS 160mgBMS 400mgBMS 1000mgBMS 400mg + Nivo 360mgBMS 1000mg + Nivo 360mg
Started762935218
Completed000000
Not completed762935218
Withdrew: Disease progression742631166
Withdrew: Study drug toxicity011122
Withdrew: Death000100
Withdrew: Adverse event unrelated to study drug000010
Withdrew: Participant request to discontinue study treatment001210
Withdrew: Withdrawal by subject010000
Withdrew: Administrative reason by sponsor000010
Withdrew: Other reasons001000

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs)

Number of participants with any grade adverse events (AEs). An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

Time frame:
From first dose to 100 days post last dose (Up to 64 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsBMS 70mgBMS 160mgBMS 400mgBMS 1000mgBMS 400mg + Nivo 360mgBMS 1000mg + Nivo 360mg
Number of Participants With Adverse Events (AEs)762935218
PrimaryNumber of Participants With Serious Adverse Events (SAEs)

Number of participants with any grade serious adverse events (SAEs). A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: * results in death * is life-threatening * requires inpatient hospitalization or causes prolongation of existing hospitalization * results in persistent or significant disability/incapacity * is a congenital anomaly/birth defect * is an important medical event Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

Time frame:
From first dose to 100 days post last dose (Up to 64 months)
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs)
ParticipantsBMS 70mgBMS 160mgBMS 400mgBMS 1000mgBMS 400mg + Nivo 360mgBMS 1000mg + Nivo 360mg
Number of Participants With Serious Adverse Events (SAEs)742124115
PrimaryNumber of Participants With Adverse Events (AEs) Leading to Discontinuation

Number of participants with any grade adverse events (AEs) leading to discontinuation. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

Time frame:
From first dose to 100 days post last dose (Up to 64 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) Leading to Discontinuation
ParticipantsBMS 70mgBMS 160mgBMS 400mgBMS 1000mgBMS 400mg + Nivo 360mgBMS 1000mg + Nivo 360mg
Number of Participants With Adverse Events (AEs) Leading to Discontinuation012532
PrimaryNumber of Participants Who Died

Number of participants who died due to any cause.

Time frame:
From first dose to 100 days post last dose (Up to 64 months)
Reported as:
Count of participants · Participants
Number of Participants Who Died
ParticipantsBMS 70mgBMS 160mgBMS 400mgBMS 1000mgBMS 400mg + Nivo 360mgBMS 1000mg + Nivo 360mg
Number of Participants Who Died32101624
PrimaryNumber of Participants With Abnormal Hepatic Test

Number of participants with laboratory abnormalities in specific hepatic tests. The number of participants with the following laboratory abnormalities from on-treatment evaluations will be summarized: * ALT or AST \> 5xULN, \> 3xULN, and \> 2xULN * Any of ALT, AST, Total Bilirubin or ALP \> 8xULN * Total bilirubin \> 3xULN ALT = Alanine Aminotransferase; AST = Aspartate Aminotransferase; ULN = Upper Limit of Normal

Time frame:
From first dose to 100 days post last dose (Up to 64 months)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Hepatic Test
ParticipantsBMS 70mgBMS 160mgBMS 400mgBMS 1000mgBMS 400mg + Nivo 360mgBMS 1000mg + Nivo 360mg
ALT OR AST > 5XULN000112
ALT OR AST > 3XULN000000
ALT OR AST > 2XULN000000
ANY OF ALT, AST, TOTAL BILIRUBIN OR ALP > 8XULN000101
TOTAL BILIRUBIN > 3XULN100001
SecondaryBMS-986012 Maximum Observed Serum Concentration (Cmax)

BMS-986012 maximum observed serum concentration (Cmax).

Time frame:
Cycle 1 day 1, cycle 3 day 1 (including pre-dose, 1, 2, 4, 8, 24, 72, 168, 336 hours post dose)
Reported as:
Geometric mean · ug/mL
BMS-986012 Maximum Observed Serum Concentration (Cmax)
ug/mLBMS 70mgBMS 160mgBMS 400mgBMS 1000mgBMS 400mg + Nivo 360mgBMS 1000mg + Nivo 360mg
cycle 1 day 127.5 ± 3153.8 ± 28121 ± 26276 ± 37111 ± 33339 ± 25
cycle 3 day 133.8 ± NA46.9 ± NA221 ± 1279 ± 37——
SecondaryBMS-986012 Time of Maximum Observed Serum Concentration (Tmax)

BMS-986012 time of maximum observed serum concentration (Tmax).

Time frame:
Cycle 1 day 1, cycle 3 day 1 (including pre-dose, 1, 2, 4, and 8 hours post dose)
Reported as:
Median · hours
BMS-986012 Time of Maximum Observed Serum Concentration (Tmax)
hoursBMS 70mgBMS 160mgBMS 400mgBMS 1000mgBMS 400mg + Nivo 360mgBMS 1000mg + Nivo 360mg
cycle 1 day 12.08 (1.00 to 8.00)2.02 (1.00 to 6.33)2.00 (1.00 to 6.07)1.58 (0.950 to 4.40)4.00 (1.00 to 5.40)1.53 (1.00 to 4.30)
cycle 3 day 11.93 (1.93 to 1.93)4.00 (4.00 to 4.00)2.04 (2.02 to 2.07)2.30 (2.05 to 4.00)——
SecondaryBMS-986012 Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC (0-T))

BMS-986012 area under the serum concentration-time curve from time zero to time of last quantifiable concentration (AUC (0-T)).

Time frame:
Cycle 1 day 1, cycle 3 day 1 (including pre-dose, 1, 2, 4, 8, 24, 72, 168, 336 hours post dose)
Reported as:
Geometric mean · h*ug/mL
BMS-986012 Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC (0-T))
h*ug/mLBMS 70mgBMS 160mgBMS 400mgBMS 1000mgBMS 400mg + Nivo 360mgBMS 1000mg + Nivo 360mg
cycle 1 day 13997 ± 315584 ± 5518456 ± 3236223 ± 4016527 ± 3145126 ± 24
cycle 3 day 17062 ± NA10560 ± NA42583 ± 858649 ± 28——
SecondaryBMS-986012 Area Under the Serum Concentration-time Curve in One Dosing Interval AUC (TAU)

BMS-986012 area under the serum concentration-time curve in one dosing interval AUC (TAU).

Time frame:
Cycle 1 day 1, cycle 3 day 1 (including pre-dose, 1, 2, 4, 8, 24, 72, 168, 336 hours post dose)
Reported as:
Geometric mean · h*ug/mL
BMS-986012 Area Under the Serum Concentration-time Curve in One Dosing Interval AUC (TAU)
h*ug/mLBMS 70mgBMS 160mgBMS 400mgBMS 1000mgBMS 400mg + Nivo 360mgBMS 1000mg + Nivo 360mg
cycle 1 day 14300 ± 298356 ± 2819865 ± 2840979 ± 3418161 ± 3049031 ± 26
cycle 3 day 17062 ± NA10560 ± NA42583 ± 862634 ± 33——
SecondaryBMS-986012 Observed Serum Concentration at the End of a Dosing Interval (Ctau)

BMS-986012 observed serum concentration at the end of a dosing interval (Ctau).

Time frame:
Cycle 1 day 1, cycle 3 day 1 (including pre-dose, 1, 2, 4, 8, 24, 72, 168, 336 hours post dose)
Reported as:
Geometric mean · ug/mL
BMS-986012 Observed Serum Concentration at the End of a Dosing Interval (Ctau)
ug/mLBMS 70mgBMS 160mgBMS 400mgBMS 1000mgBMS 400mg + Nivo 360mgBMS 1000mg + Nivo 360mg
cycle 1 day 13.44 ± 386.24 ± 3117.4 ± 3230.2 ± 5914.6 ± 4439.5 ± 40
cycle 3 day 17.39 ± NA13.6 ± NA42.4 ± 1359.2 ± 19——
SecondaryBMS-986012 Total Body Clearance (CLT)

BMS-986012 total body clearance (CLT).

Time frame:
Cycle 1 day 1, cycle 3 day 1 (including pre-dose, 1, 2, 4, 8, 24, 72, 168, 336 hours post dose)
Reported as:
Geometric mean · mL/h
BMS-986012 Total Body Clearance (CLT)
mL/hBMS 70mgBMS 160mgBMS 400mgBMS 1000mgBMS 400mg + Nivo 360mgBMS 1000mg + Nivo 360mg
cycle 1 day 116.3 ± 3819.1 ± 2720.1 ± 2424.4 ± 8622.0 ± 3020.4 ± 28
cycle 3 day 19.91 ± NA15.2 ± NA9.39 ± 816.0 ± 40——
SecondaryBMS-986012 Trough Observed Serum Concentration (Ctrough)

BMS-986012 trough observed serum concentration (Ctrough).

Time frame:
Cycle 2 day 1, cycle 3 day 1, cycle 4 day 1, cycle 7 day 1, cycle 11 day 1. cycle 15 day 1 (including pre-dose, 1, 2, 4, 8, 24, 72, 168, 336 hours post dose)
Reported as:
Geometric mean · ng/mL
BMS-986012 Trough Observed Serum Concentration (Ctrough)
ng/mLBMS 70mgBMS 160mgBMS 400mgBMS 1000mgBMS 400mg + Nivo 360mgBMS 1000mg + Nivo 360mg
cycle 2 day 14186 ± 277211 ± 1718810 ± 2936990 ± 5414544 ± 8436391 ± 43
cycle 3 day 16570 ± NA9100 ± NA29232 ± 3668589 ± 5726016 ± 37158801 ± 85
cycle 4 day 17390 ± NA13600 ± NA35122 ± 2690207 ± 6826102 ± 63157000 ± NA
cycle 7 day 19040 ± NA13700 ± NA38315 ± 27107444 ± 5838405 ± 9—
cycle 11 day 19930 ± NA—32251 ± 14102980 ± 6734400 ± NA—
cycle 15 day 18029 ± NA—————
SecondaryBMS-986012 Average Concentration Over a Dosing Interval (Css-avg)

BMS-986012 Average concentration over a dosing interval (\[AUC(TAU)/tau\] (Css-avg).

Time frame:
Cycle 3 day 1 (including pre-dose, 1, 2, 4, and 8 hours post dose)
Reported as:
Geometric mean · ug/mL
BMS-986012 Average Concentration Over a Dosing Interval (Css-avg)
ug/mLBMS 70mgBMS 160mgBMS 400mgBMS 1000mgBMS 400mg + Nivo 360mgBMS 1000mg + Nivo 360mg
BMS-986012 Average Concentration Over a Dosing Interval (Css-avg)13.9 ± NA22.0 ± NA82.1 ± 11119 ± 33——
SecondaryBMS-986012 Accumulation Index (AI_AUC)

BMS-986012 accumulation index. Ratio of an exposure measure at steady state to that after the first dose.

Time frame:
Cycle 3 day 1 (including pre-dose, 1, 2, 4, and 8 hours post dose)
Reported as:
Geometric mean · Ratio
BMS-986012 Accumulation Index (AI_AUC)
RatioBMS 70mgBMS 160mgBMS 400mgBMS 1000mgBMS 400mg + Nivo 360mgBMS 1000mg + Nivo 360mg
BMS-986012 Accumulation Index (AI_AUC)1.56 ± NA1.55 ± NA1.62 ± 221.39 ± 51——
SecondaryBMS-986012 Cmax Accumulation Index (AI_Cmax)

BMS-986012 Cmax accumulation index (AI_Cmax). Ratio of an exposure measure at steady state to that after the first dose.

Time frame:
Cycle 3 day 1 (including pre-dose, 1, 2, 4, and 8 hours post dose)
Reported as:
Geometric mean · Ratio
BMS-986012 Cmax Accumulation Index (AI_Cmax)
RatioBMS 70mgBMS 160mgBMS 400mgBMS 1000mgBMS 400mg + Nivo 360mgBMS 1000mg + Nivo 360mg
BMS-986012 Cmax Accumulation Index (AI_Cmax)0.994 ± NA1.47 ± NA1.22 ± 110.940 ± 70——
SecondaryBMS-986012 Ctau Accumulation Index (AI_Ctau)

BMS-986012 Ctau accumulation index (AI_Ctau). Ratio of an exposure measure at steady state to that after the first dose.

Time frame:
Cycle 3 day 1 (including pre-dose, 1, 2, 4, and 8 hours post dose)
Reported as:
Geometric mean · Ratio
BMS-986012 Ctau Accumulation Index (AI_Ctau)
RatioBMS 70mgBMS 160mgBMS 400mgBMS 1000mgBMS 400mg + Nivo 360mgBMS 1000mg + Nivo 360mg
BMS-986012 Ctau Accumulation Index (AI_Ctau)1.81 ± NA2.31 ± NA1.76 ± 01.08 ± 82——
SecondaryBMS-986012 Effective Elimination (T-HALFeff)

BMS-986012 effective elimination (T-HALFeff) that explains the degree of accumulation observed for a specific exposure measure.

Time frame:
Cycle 3 day 1 (including pre-dose, 1, 2, 4, and 8 hours post dose)
Reported as:
Mean · Hours
BMS-986012 Effective Elimination (T-HALFeff)
HoursBMS 70mgBMS 160mgBMS 400mgBMS 1000mgBMS 400mg + Nivo 360mgBMS 1000mg + Nivo 360mg
BMS-986012 Effective Elimination (T-HALFeff)342 ± NA319 ± NA384 ± 154.2583 ± NA——
SecondaryBest Overall Response (BOR)

BOR defined as the best response designation over the study as a whole. Complete Response (CR) = Disappearance of all target lesions; Partial Response (PR) = At least a 30% decrease in the sum of diameters of target lesions; Stable Disease (SD) = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; Progressive Disease (PD) = At least a 20% increase in the sum of diameters of target lesions and the sum must demonstrate an absolute increase of at least 5 mm

Time frame:
From first dose to the last tumor assessment prior to subsequent therapy (Up to 97 months)
Reported as:
Count of participants · Participants
Best Overall Response (BOR)
ParticipantsBMS 70mgBMS 160mgBMS 400mgBMS 1000mgBMS 400mg + Nivo 360mgBMS 1000mg + Nivo 360mg
Complete Response100010
Partial Response001182
Stable Disease028821
Progressive Disease42182193
Not evaluable222512
SecondaryObjective Response Rate (ORR)

ORR is defined as the percent of participants whose BOR is either CR or PR. Complete Response (CR) = Disappearance of all target lesions; Partial Response (PR) = At least a 30% decrease in the sum of diameters of target lesions; Progressive Disease (PD) = At least a 20% increase in the sum of diameters of target lesions and the sum must demonstrate an absolute increase of at least 5 mm

Time frame:
From first dose date to the date of first documented disease progression (Up to 97 months)
Reported as:
Number · Percent of participants
Objective Response Rate (ORR)
Percent of participantsBMS 70mgBMS 160mgBMS 400mgBMS 1000mgBMS 400mg + Nivo 360mgBMS 1000mg + Nivo 360mg
Objective Response Rate (ORR)14.3 (0.4 to 57.9)0 (0.0 to 45.9)3.4 (0.1 to 17.8)2.9 (0.1 to 14.9)42.9 (21.8 to 66.0)25.0 (3.2 to 65.1)
SecondaryDuration of Response (DoR)

DoR is defined as the time from first response (CR or PR) to the date of the first documented tumor progression as determined using RECIST 1.1 criteria or death due to any cause, whichever occurs first. Participants who remain alive and have not progressed will be censored on the date of their last tumor assessment. Complete Response (CR) = Disappearance of all target lesions; Partial Response (PR )= At least a 30% decrease in the sum of diameters of target lesions; Progressive Disease (PD) = At least a 20% increase in the sum of diameters of target lesions and the sum must demonstrate an absolute increase of at least 5 mm Median DOR will only be evaluated provided there are enough responding participants to warrant inclusion.

Time frame:
From the date of first dose to the date of the first documented tumor progression or death due to any cause, whichever occurs first (Up to 97 months)
Reported as:
Median · Weeks
Duration of Response (DoR)
WeeksBMS 70mgBMS 160mgBMS 400mgBMS 1000mgBMS 400mg + Nivo 360mgBMS 1000mg + Nivo 360mg
Duration of Response (DoR)————120.57 (12.14 to NA)—
SecondaryProgression Free Survival (PFS)

PFS is defined as the time from the date of first dose of study medication to the date of the first objective documentation of tumor progression or death due to any cause, if death occurred within 100 days after last BMS-986012 dose. Progressive Disease (PD) = At least a 20% increase in the sum of diameters of target lesions and the sum must demonstrate an absolute increase of at least 5 mm

Time frame:
From first dose to the date of first documented disease progression or death due to any cause, if death occurred within 100 days after last BMS-986012 dose (Up to 97 months)
Reported as:
Median · Weeks
Progression Free Survival (PFS)
WeeksBMS 70mgBMS 160mgBMS 400mgBMS 1000mgBMS 400mg + Nivo 360mgBMS 1000mg + Nivo 360mg
Progression Free Survival (PFS)5.50 (2.43 to 53.00)5.86 (5.29 to 30.29)5.79 (5.57 to 8.00)5.36 (5.00 to 5.71)17.71 (6.14 to 120.29)5.71 (2.71 to 25.00)
SecondaryProgression Free Survival Rate (PFSR)

PFSR is defined as the percent of participants who remain progression free and surviving at "t" weeks (t= 12, 24, 36, 48, 60, 72). Progressive Disease (PD)=At least a 20% increase in the sum of diameters of target lesions and the sum must demonstrate an absolute increase of at least 5 mm

Time frame:
Weeks 12, 24, 36, 48, 60, 72
Reported as:
Number · Percent of participants
Progression Free Survival Rate (PFSR)
Percent of participantsBMS 70mgBMS 160mgBMS 400mgBMS 1000mgBMS 400mg + Nivo 360mgBMS 1000mg + Nivo 360mg
Week 12NA (NA to NA)NA (NA to NA)21.4 (8.7 to 37.8)20.6 (9.1 to 35.3)55.0 (31.3 to 73.5)NA (NA to NA)
Week 24NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)45.0 (23.1 to 64.7)NA (NA to NA)
Week 36NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)45.0 (23.1 to 64.7)NA (NA to NA)
Week 48NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)35.0 (15.7 to 55.2)NA (NA to NA)
Week 60NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)35.0 (15.7 to 55.2)NA (NA to NA)
Week 72NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)35.0 (15.7 to 55.2)NA (NA to NA)
SecondaryNumber of Participants With Anti-BMS-986012 Antibodies (ADA)

Number of participants with anti-BMS-986012 antibodies (ADA) with status as baseline ADA positive, ADA positive and ADA negative. Baseline ADA positive participant is a participant with baseline ADA positive sample (Day 1 predose). ADA-positive participant is a participant with at least one ADA positive sample relative to baseline at any time after initiation of treatment during the defined observation time period. ADA negative participant is a participant with no ADA positive sample after the initiation of treatment.

Time frame:
From first dose to 100 days following the last BMS-986012 dose (Up to 64 months)
Reported as:
Count of participants · Participants
Number of Participants With Anti-BMS-986012 Antibodies (ADA)
ParticipantsBMS 70mgBMS 160mgBMS 400mgBMS 1000mgBMS 400mg + Nivo 360mgBMS 1000mg + Nivo 360mg
Baseline ADA positive000100
ADA positive000000
ADA negative552725147

Adverse events

Collected over SAEs and Other AEs are assessed from first dose up to 100 days post last dose (Up to 64 months). Participants were assessed for all-cause mortality from their first dose to their study completion (Up to 97 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BMS 70mg SCLC Refractory3/3 (100%)3/3 (100%)3/3 (100%)
BMS 70mg SCLC Sensitive4/4 (100%)4/4 (100%)4/4 (100%)
BMS 160mg SCLC Refractory1/2 (50%)2/2 (100%)2/2 (100%)
BMS 160mg SCLC Sensitive1/4 (25%)2/4 (50%)4/4 (100%)
BMS 400mg SCLC Refractory3/3 (100%)3/3 (100%)3/3 (100%)
BMS 400mg SCLC Sensitive3/4 (75%)4/4 (100%)4/4 (100%)
BMS 400mg SCLC Refractory Expansion9/12 (75%)8/12 (66.7%)12/12 (100%)
BMS 400mg SCLC Sensitive Expansion9/10 (90%)6/10 (60%)10/10 (100%)
BMS 1000mg SCLC Refractory3/3 (100%)3/3 (100%)3/3 (100%)
BMS 1000mg SCLC Sensitive5/6 (83.3%)2/6 (33.3%)6/6 (100%)
BMS 1000mg SCLC Refractory Expansion11/12 (91.7%)8/12 (66.7%)12/12 (100%)
BMS 1000mg SCLC Sensitive Expansion12/14 (85.7%)11/14 (78.6%)14/14 (100%)
BMS 400mg + Nivo 360mg SCLC Refractory2/2 (100%)1/2 (50%)2/2 (100%)
BMS 400mg + Nivo 360mg SCLC Sensitive6/6 (100%)4/6 (66.7%)6/6 (100%)
BMS 400mg + Nivo 360mg SCLC Refractory Expansion3/4 (75%)2/4 (50%)4/4 (100%)
BMS 400mg + Nivo 360mg SCLC Sensitive Expansion4/9 (44.4%)4/9 (44.4%)9/9 (100%)
BMS 1000mg + Nivo 360mg SCLC Refractory3/3 (100%)3/3 (100%)3/3 (100%)
BMS 1000mg + Nivo 360mg SCLC Sensitive5/5 (100%)2/5 (40%)5/5 (100%)
Most frequent serious events
Showing 10 of 64
Most frequent serious events
EventBMS 70mg SCLC RefractoryBMS 70mg SCLC SensitiveBMS 160mg SCLC RefractoryBMS 160mg SCLC SensitiveBMS 400mg SCLC RefractoryBMS 400mg SCLC SensitiveBMS 400mg SCLC Refractory ExpansionBMS 400mg SCLC Sensitive ExpansionBMS 1000mg SCLC RefractoryBMS 1000mg SCLC SensitiveBMS 1000mg SCLC Refractory ExpansionBMS 1000mg SCLC Sensitive ExpansionBMS 400mg + Nivo 360mg SCLC RefractoryBMS 400mg + Nivo 360mg SCLC SensitiveBMS 400mg + Nivo 360mg SCLC Refractory ExpansionBMS 400mg + Nivo 360mg SCLC Sensitive ExpansionBMS 1000mg + Nivo 360mg SCLC RefractoryBMS 1000mg + Nivo 360mg SCLC Sensitive
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/33/41/22/42/31/45/123/103/31/66/126/140/23/61/41/92/32/5
Pericardial effusionCardiac disorders0/31/40/20/40/30/40/120/100/30/60/120/141/20/60/40/90/30/5
FatigueGeneral disorders0/32/40/20/40/30/40/120/100/30/60/120/140/20/60/40/90/30/5
PainGeneral disorders0/30/41/20/41/30/40/120/101/30/60/120/140/20/60/40/90/30/5
Diarrhoea infectiousInfections and infestations0/30/40/20/40/30/40/120/100/30/60/120/141/20/60/40/90/30/5
Enterocolitis infectiousInfections and infestations0/30/41/20/40/30/40/120/100/30/60/120/140/20/60/40/90/30/5
Gastric haemorrhageGastrointestinal disorders0/30/40/20/40/30/40/120/100/30/60/120/140/20/60/40/91/30/5
Oedema peripheralGeneral disorders1/30/40/20/40/30/40/120/100/30/60/120/140/20/60/40/90/30/5
PyrexiaGeneral disorders0/30/40/20/41/30/40/120/100/30/60/120/140/20/60/40/90/30/5
Hepatic failureHepatobiliary disorders0/30/40/20/40/30/40/120/100/30/60/120/140/20/60/40/91/30/5
Most frequent other events
Showing 10 of 337
Most frequent other events
EventBMS 70mg SCLC RefractoryBMS 70mg SCLC SensitiveBMS 160mg SCLC RefractoryBMS 160mg SCLC SensitiveBMS 400mg SCLC RefractoryBMS 400mg SCLC SensitiveBMS 400mg SCLC Refractory ExpansionBMS 400mg SCLC Sensitive ExpansionBMS 1000mg SCLC RefractoryBMS 1000mg SCLC SensitiveBMS 1000mg SCLC Refractory ExpansionBMS 1000mg SCLC Sensitive ExpansionBMS 400mg + Nivo 360mg SCLC RefractoryBMS 400mg + Nivo 360mg SCLC SensitiveBMS 400mg + Nivo 360mg SCLC Refractory ExpansionBMS 400mg + Nivo 360mg SCLC Sensitive ExpansionBMS 1000mg + Nivo 360mg SCLC RefractoryBMS 1000mg + Nivo 360mg SCLC Sensitive
NauseaGastrointestinal disorders1/34/41/21/42/31/42/123/102/32/67/125/141/22/62/44/91/33/5
FatigueGeneral disorders2/33/40/21/40/31/44/123/100/33/67/1212/141/22/64/44/92/32/5
ArthralgiaMusculoskeletal and connective tissue disorders2/31/40/21/40/31/43/121/100/30/62/121/141/22/62/49/91/33/5
Back painMusculoskeletal and connective tissue disorders1/30/41/21/42/30/41/124/100/32/64/122/142/23/61/43/90/32/5
HeadacheNervous system disorders0/32/40/21/40/32/40/121/101/30/62/121/142/22/61/40/91/32/5
PruritusSkin and subcutaneous tissue disorders2/34/42/22/43/34/412/128/103/36/69/1213/141/25/64/49/93/35/5
ConstipationGastrointestinal disorders1/33/41/21/41/31/45/126/102/31/62/123/140/22/61/44/92/31/5
HypomagnesaemiaMetabolism and nutrition disorders1/30/40/20/40/33/42/120/100/30/64/120/141/20/60/43/90/31/5
Decreased appetiteMetabolism and nutrition disorders2/31/41/21/41/32/46/127/101/32/65/126/140/22/62/41/92/31/5
Oedema peripheralGeneral disorders0/31/40/20/42/30/41/122/101/30/64/122/141/22/60/42/90/31/5

Baseline characteristics

Age, Continuous
Age, Continuous(Years)BMS 70mgBMS 160mgBMS 400mgBMS 1000mgBMS 400mg + Nivo 360mgBMS 1000mg + Nivo 360mgTotal
Mean65.1 ± 10.658.3 ± 8.164.4 ± 9.261.7 ± 9.562.1 ± 9.861.1 ± 7.362.5 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)BMS 70mgBMS 160mgBMS 400mgBMS 1000mgBMS 400mg + Nivo 360mgBMS 1000mg + Nivo 360mgTotal
Female4411129545
Male32182312361
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BMS 70mgBMS 160mgBMS 400mgBMS 1000mgBMS 400mg + Nivo 360mgBMS 1000mg + Nivo 360mgTotal
Hispanic or Latino1010103
Not Hispanic or Latino66263320899
Unknown or Not Reported0022004
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BMS 70mgBMS 160mgBMS 400mgBMS 1000mgBMS 400mg + Nivo 360mgBMS 1000mg + Nivo 360mgTotal
American Indian or Alaska Native0000000
Asian0013004
Native Hawaiian or Other Pacific Islander0000000
Black or African American0010001
White76273021899
More than one race0000000
Unknown or Not Reported0002002
08

Study locations

16 sites
  • Local Institution - 0004
    New York, New York 10065, United States
  • Local Institution - 0001
    Durham, North Carolina 27710, United States
  • Local Institution - 0021
    Winston-Salem, North Carolina 27157, United States
  • Local Institution - 0020
    St. Leonards, New South Wales 2065, Australia
  • Local Institution - 0011
    Brisbane, Queensland 4102, Australia
  • Local Institution - 0002
    Clayton, Victoria 3168, Australia
  • Local Institution - 0015
    Gent, 9000, Belgium
  • Local Institution - 0012
    Liege, 4000, Belgium
  • Local Institution - 0003
    Edmonton, Alberta T6G 1Z2, Canada
  • Local Institution - 0017
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Local Institution - 0019
    Hamilton, Ontario L8V 5C2, Canada
  • Local Institution - 0010
    London, Ontario N6A 4L6, Canada
  • Local Institution - 0007
    Toronto, Ontario M5G 2M9, Canada
  • Local Institution - 0008
    Seoul, 03080, Korea, Republic of
  • Local Institution - 0013
    Nijmegen, 6525 GA, Netherlands
  • Local Institution - 0009
    San Juan, 00927, Puerto Rico
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2014 to primary completion in Dec 2022, 97 months.

Results were first posted in Mar 2024, 1 year 2 months after primary completion.

Of 71 industry-sponsored phase 1/2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 74. This study's 97 months is above that.

Counting every sponsor, half of 98 studies reached it within 54 months; a quarter within 44 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2014
First posted
Sep 25, 2014
StartActual
Nov 14, 2014
Primary completionActual
Dec 21, 2022
CompletionActual
Dec 22, 2022
Results first posted
Mar 5, 2024
Last update
Mar 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02247349
Responsible party
Sponsor
First posted
Sep 25, 2014
Start date
Nov 14, 2014
Primary completion
Dec 21, 2022
Completion
Dec 22, 2022
Results posted
Mar 5, 2024
Last update
Mar 5, 2024

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atigotatug

Start the discussion